NUB1

Across TCGA pan-cancer cohorts, NUB1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NUB1 data layer compared with 24 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NUB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NUB1 expression acts as an unfavorable survival marker.

BLCA, LUAD, and HNSC are the cancer types where NUB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.243	0.712	<.001	36	view →
LUAD	OS	Median	All	0.163	0.835	<.001	36	view →
HNSC	DFS	Median	All	0.148	0.696	.004	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
KIRP	OS	Median	All	0.248	0.705	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NUB1–BLCA (OS)

Open the BLCA breakdown →